Abstract
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed medications for psychiatric disorders, yet they leave the majority of patients without full symptom relief. Therefore, a major research challenge is to identify novel targets for the improved treatment of these disorders. SSRIs act by blocking the serotonin transporter (SERT), the high-affinity, low-capacity, uptake-1 transporter for serotonin. Other classes of antidepressant work by blocking the norepinephrine or dopamine transporters (NET and DAT), the high-affinity, low-capacity uptake-1 transporters for norepinephrine and dopamine, or by blocking combinations of SERT, NET, and DAT. It has been proposed that uptake-2 transporters, which include organic cation transporters (OCTs) and the plasma membrane monoamine transporter (PMAT), undermine the therapeutic utility of uptake-1 acting antidepressants. Uptake-2 transporters for monoamines have low affinity for these neurotransmitters, but a high capacity to transport them. Thus, activity of these transporters may limit the increase of extracellular monoamines thought to be essential for ultimate therapeutic benefit. Here preclinical evidence supporting a role for OCT2, OCT3, and PMAT in behaviors relevant to psychiatric disorders is presented. Importantly, preclinical evidence revealing these transporters as targets for the development of novel therapeutics for psychiatric disorders is discussed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adamsen D, Ramaekers V, Ho HT, Britschgi C, Rufenacht V, Meili D, Bobrowski E, Philippe P, Nava C, Van Maldergem L, Bruggmann R, Walitza S, Wang J, Grunblatt E, Thony B (2014) Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene. Mol Autism 5:43. https://doi.org/10.1186/2040-2392-5-43
Amphoux A, Vialou V, Drescher E, Brüss M, Mannoury La Cour C, Rochat C, Millan MJ, Giros B, Bönisch H, Gautron S (2006) Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology 50:941–952. https://doi.org/10.1016/j.neuropharm.2006.01.005
André P, Saubaméa B, Cochois-Guégan V, Marie-Claire C, Cattelotte J, Smirnova M, Schinkel AH, Scherrmann J-M, Cisternino S (2012) Transport of biogenic amine neurotransmitters at the mouse blood-retina and blood-brain barriers by uptake1 and uptake2. J Cereb Blood Flow Metab 32:1989–2001. https://doi.org/10.1038/jcbfm.2012.109
Bacq A, Balasse L, Biala G, Guiard B, Gardier AM, Schinkel A, Louis F, Vialou V, Martres MP, Chevarin C, Hamon M, Giros B, Gautron S (2012) Organic cation transporter 2 controls brain norepinephrine and serotonin clearance and antidepressant response. Mol Psychiatry 17:926–939. https://doi.org/10.1038/mp.2011.87
Baganz NL, Horton RE, Calderon AS, Owens WA, Munn JL, Watts LT, Koldzic-Zivanovic N, Jeske NA, Koek W, Toney GM, Daws LC (2008) Organic cation transporter 3: keeping the brake on extracellular serotonin in serotonin transporter deficient mice. Proc Natl Acad Sci U S A 105(48):18976–18981. https://doi.org/10.1073/pnas.0800466105
Baganz N, Horton R, Martin K, Holmes A, Daws LC (2010) Repeated swim impairs serotonin clearance via a corticosterone-sensitive mechanism: organic cation transporter 3, the smoking gun. J Neurosci 30(45):15185–15195. https://doi.org/10.1523/JNEUROSCI.2740-10.2010
Baghai TC, Volz HP, Möller HJ (2006) Drug treatment of depression in the 2000s: an overview of achievements in the last 10 years and future possibilities. World J Biol Psychiatry 7(4):198–222. https://doi.org/10.1080/15622970601003973
Belzer M, Morales M, Jagadish B, Mash EA, Wright SH (2013) Substrate-dependent ligand inhibition of the human organic cation transporter OCT2. J Pharmacol Exp Ther 346:300–310. jpet.113.203257 [pii]. https://doi.org/10.1124/jpet.113.203257
Benton KC, Lowry CA, Gasser PJ (2021) Organic cation transporters and nongenomic glucocorticoid actions. Handb Exp Pharmacol. https://doi.org/10.1007/164_2021_493
Bergen AW, Javitz HS, Krasnow R, Michel M, Nishita D, Conti DV, Edlund CK, Kwok P-Y, McClure JB, Kim RB, Hall SM, Tyndale RF, Baker TB, Benowitz NL, Swan GE (2014) Organic cation transporter variation and response to smoking cessation therapies. Nicotine Tob Res 16:1638–1646. https://doi.org/10.1093/ntr/ntu161
Bertler A, Falck B, Owman C (1964) Studies on 5-hydroxytryptamine stores in pineal gland of rat. Acta Physiol Scand Suppl 239:1–18. https://doi.org/10.1111/j.1748-1716.1964.tb04118.x
Bönisch H (2021) Substrates and inhibitors of organic cation transporters and plasma membrane monoamine transporter and therapeutic implications. Handb Exp Pharmacol
Borghetti A, Calcagno A, Lombardi F, Cusato J, Belmonti S, D'Avolio A, Ciccarelli N, La Monica S, Colafigli M, Delle Donne V, De Marco R, Tamburrini E, Visconti E, Di Perri G, De Luca A, Bonora S, Di Giambenedetto S (2019) SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. J Antimicrob Chemother 74(4):1035–1043. https://doi.org/10.1093/jac/dky508
Bowman MA, Mitchell NC, Owens WA, Horton RE, Koek W, Daws LC (2020a) Effect of concurrent organic cation transporter blockade on norepinephrine clearance inhibiting- and antidepressant-like actions of desipramine and venlafaxine. Eur J Pharmacol 883:173285. https://doi.org/10.1016/j.ejphar.2020.173285
Bowman MA, Vitela M, Clarke KM, Koek W, Daws LC (2020b) Serotonin transporter and plasma membrane monoamine transporter are necessary for the antidepressant-like effects of ketamine in mice. Int J Mol Sci 21(20):7581. https://doi.org/10.3390/ijms21207581
Bunin MA, Wightman RM (1998) Quantitative evaluation of 5-hydroxytryptamine (serotonin) neuronal release and uptake: and investigation of extrasynaptic transmission. J Neurosci 18:4854–4860. https://doi.org/10.1523/JNEUROSCI.18-13-04854
Burcusa SL, Lacono WG (2007) Risk for recurrence in depression. Clin Psychol Rev 27(8):959–985. https://doi.org/10.1016/j.cpr.2007.02.005
Burgen ASV, Iversen LL (1965) The inhibition of noradrenaline uptake by sympathomimetic amines in the rat isolated heart. Br J Pharmacol 25:34–49. https://doi.org/10.1111/j.1476-5381.1965.tb01754.x
Busch AE, Karbach U, Miska D, Gorboulev V, Akhoundova A, Volk C, Arndt P, Ulzheimer JC, Sonders MS, Baumann C, Waldegger S, Lang F, Koepsell H (1998) Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol 54:342–352. https://doi.org/10.1124/mol.54.2.342
Butler J, Tannian M, Leonard BE (1988) The chronic effects of desipramine and sertraline on platelet and synaptosomal 5HT uptake in olfactory bulbectomized rats. Prog Neuro-Psychopharmacol Biol Psychiat 12:585–594. https://doi.org/10.1016/0278-5846(88)90004-8
Byrne SE, Rothschild AJ (1998) Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatment. J Clin Psychiatry 59:279–288. https://doi.org/10.4088/jcp.v59n0602
Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R (2003) Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301:386–389. https://doi.org/10.1126/science.1083968
Caspi A, Hariri AR, Holmes A, Uher R, Moffitt TE (2010) Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry 167:509–527. https://doi.org/10.1176/appi.ajp.2010.09101452
Cervilla JA, Molina E, Rivera M, Torres-González F, Bellón JA, Moreno B, Luna JD, Lorente JA, Mayoral F, King M, Nazareth I, Gutiérrez B, PREDICT Study Core Group (2007) The risk for depression conferred by stressful life events is modified by variation at the serotonin transporter 5HTTLPR genotype: evidence from the Spanish PREDICT-gene cohort. Mol Psychiatry 12:748–755. https://doi.org/10.1038/sj.mp.4001981
Clements JD (1996) Transmitter time course in the synaptic cleft: its role in central synaptic function. Trends Neurosci 19:163–171. https://doi.org/10.1016/S0166-2236(96)10024-2
Couroussé T, Bacq A, Belzung C, Guiard B, Balasse L, Louis F, Le Guisquet A-M, Gardier AM, Schinkel AH, Giros B, Gautron S (2015) Brain organic cation transporter 2 controls response and vulnerability to stress and GSK3β signaling. Mol Psychiatry 20:889–900. https://doi.org/10.1038/mp.2014.86. Epub ahead of print 2014
Cragg SJ, Rice ME (2004) DAncing past the DAT at a DA synapse. Trends Neurosci 27:270–277. https://doi.org/10.1016/j.tins.2004.03.011
Cui M, Aras R, Christian WV, Rappold PM, Hatwar M, Panza J, Jackson-Lewis V, Javitch JA, Ballatori N, Przedborski S, Tieu K (2009) The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc Natl Acad Sci U S A 106:8043–8048. https://doi.org/10.1073/pnas.0900358106
Dahlin A, Xia L, Kong W, Hevner R, Wang J (2007) Expression and immunolocalization of the plasma membrane monoamine transporter in the brain. Neuroscience 146:1193–1211. https://doi.org/10.1016/j.neuroscience.2007.01.072
Daws LC (2009) Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy. Pharmacol Ther 121(1):89–99. https://doi.org/10.1016/j.pharmthera.2008.10.004
Daws LC, Gould GG (2011) Ontogeny and regulation of the serotonin transporter: providing insights into human disorders. Pharmacol Ther 131(1):61–79. https://doi.org/10.1016/j.pharmthera.2011.03.013
Daws LC, Toney GM (2007) Voltammetric methods to study kinetics and mechanisms for serotonin clearance in vivo. In: Michael AC, Simon SA, Nicolelis MAL (eds) Electrochemical methods in neuroscience, for methods and new frontiers in neuroscience. CRC Press, Boca Raton
Daws LC, Koek W, Mitchell NC (2013) Revisiting serotonin reuptake inhibitors and the therapeutic potential of “Uptake-2” in psychiatric disorders. ACS Chem Nerosci 4(1):16–21. https://doi.org/10.1021/cn3001872
Donohue JM, Pincus HA (2007) Reducing the societal burden of depression: a review of economic costs, quality of care and effects of treatment. Pharmacoeconomics 25:7–24. https://doi.org/10.2165/00019053-200725010-00003
Duan H, Wang J (2013) Impaired monoamine and organic cation uptake in choroid plexus in mice with targeted disruption of the plasma membrane monoamine transporter (Slc29a4) gene. J Biol Chem 288:3535–3544. https://doi.org/10.1074/jbc.M112.436972
Engel K, Zhou M, Wang J (2004) Identification and characterization of a novel monoamine transporter in the human brain. J Biol Chem 279:50042–50049. https://doi.org/10.1074/jbc.M407913200
Feng N, Mo B, Johnson PL, Orchinik M, Lowry CA, Renner KJ (2005) Local inhibition of organic cation transporters increases extracellular serotonin in the medial hypothalamus. Brain Res 1063:69–76. https://doi.org/10.1016/j.brainres.2005.09.016
Feng N, Telefont M, Kelly KJ, Orchinik M, Forster GL, Renner KJ, Lowry CA (2009) Local perfusion of corticosterone in the rat medial hypothalamus potentiates D-fenfluramine-induced elevations of extracellular 5-HT concentrations. Horm Behav 56(1):149–157. https://doi.org/10.1016/j.yhbeh.2009.03.023
Feng N, Lowry CA, Lukkes JL, Orchinik M, Forster GL, Renner KJ (2010) Organic cation transporter inhibition increases medial hypothalamic serotonin under basal conditions and during mild restraint. Brain Res 1326:105–113. https://doi.org/10.1016/j.brainres.2010.02.044
Fraser-Spears R, Krause-Heuer AM, Basiouny M, Mayer FP, Manishimwe R, Wyatt NA, Dobrowolski JC, Roberts MP, Greguric I, Kumar N, Koek W, Sitte HH, Callaghan PD, Fraser BH, Daws LC (2019) Comparative analysis of novel decynium-22 analogs to inhibit transport by the low-affinity, high-capacity biogenic amine transporters, organic cation transporters 2 and 3, and plasma membrane monoamine transporter. Eur J Pharmacol 842:351–364. https://doi.org/10.1016/j.ejphar.2018.10.028
Fuxe K, Ungerstedt U (1967) Localization of 5-hydroxtryptamine uptake in rat brain after intraventricular injection. J Pharm Pharmacol 19:335–337. https://doi.org/10.1111/j.2042-7158.1967.tb08097.x
Garbarino VR, Gilman TL, Daws LC, Gould GG (2019a) Extreme enhancement or depletion of serotonin transporter function and serotonin availability in autism spectrum disorder. Pharmacol Res 140:85–99. https://doi.org/10.1016/j.phrs.2018.07.010
Garbarino VR, Santos TA, Nelson AR, Zhang WQ, Smolik CM, Javors MA, Daws LC, Gould GG (2019b) Prenatal metformin exposure or organic cation transporter 3 knockout curbs social interaction preference in male mice. Pharmacol Res 140:21–32. https://doi.org/10.1016/j.phrs.2018.11.013
Gasser PJ, Lowry CA, Orchinik M (2006) Corticosterone-sensitive monoamine transport in the rat dorsomedial hypothalamus: potential role for organic cation transporter 3 in stress-induced modulation of monoaminergic neurotransmission. J Neurosci 26:8758–8766. https://doi.org/10.1523/JNEUROSCI.0570-06.2006
Gasser PJ, Orchinik M, Raju I, Lowry CA (2009) Distribution of organic cation transporter 3, a corticosterone-sensitive monoamine transporter, in the rat brain. J Comp Neurol 512:529–555. https://doi.org/10.1002/cne.21921
Gasser PJ, Hurley MM, Chan J, Pickel VM (2017) Organic cation transporter 3 (OCT3) is localized to intracellular and surface membranes in select glial and neuronal cells within the basolateral amygdaloid complex of both rats and mice. Brain Struct Funct 222:1913–1928. https://doi.org/10.1007/s00429-016-1315-9
Georgiou P, Zanos P, Jenne C, Highland J, Gerhard D, Duman RS, Gould T (2018) Human experimenter sex modulates mouse behavioral responses to stress and to the antidepressant ketamine. Biol Psychiatry 83(9):S277. https://doi.org/10.1016/j.biopsych.2018.02.715
Gilman TL, George CM, Vitela M, Herrera-Rosales M, Basiouny MS, Koek W, Daws LC (2018) Constitutive plasma membrane monoamine transporter (PMAT, Slc29a4) deficiency subtly affects anxiety-like and coping behaviours. Eur J Neurosci 48:1706–1716. https://doi.org/10.1111/ejn.13968
Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Tueber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE, Koepsell H (1997) Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 16:871–881. https://doi.org/10.1089/dna.1997.16.871
Greenberg BD, Tolliver TJ, Huang SJ, Li Q, Bengel D, Murphy DL (1999) Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet 88:83–87
Gründemann D, Babin-Ebell J, Martel F, Örding N, Schmidt A, Schömig E (1997) Primary structure and functional expression of the apical organic cation transporter from kidney epithelial LLC-PK1 cells. J Biol Chem 272:10408–10413. https://doi.org/10.1074/jbc.272.16.10408
Gründemann D, Schechinger B, Rappold GA, Schömig E (1998) Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci 1:349–351. https://doi.org/10.1038/1557
Haenisch B, Bönisch H (2010) Interaction of the human plasma membrane monoamine transporter (hPMAT) with antidepressants and antipsychotics. Naunyn Schmiedebergs Arch Pharmacol 381:33–39. https://doi.org/10.1007/s00210-009-0479-8
Haenisch B, Drescher E, Thiemer L, Xin H, Giros B, Gautron S, Bönisch H (2012) Interaction of antidepressant and antipsychotic drugs with the human organic cation transporters hOCT1, hOCT2 and hOCT3. Naunyn Schmiedebergs Arch Pharmacol 385:1017–1023. https://doi.org/10.1007/s00210-012-0781-8
Hagen CE, Schenck JO, Neumaier JF (2011) The contribution of low-affinity transport mechanisms to serotonin clearance in synaptosomes. Synapse 65:1015–1023. https://doi.org/10.1002/syn.20929
Hassell JE Jr, Nguyen KT, Gates CA, Lowry CA (2019) The impact of stressor exposure and glucocorticoids on anxiety and fear. Curr Top Behav Neurosci 43:271–321. https://doi.org/10.1007/7854_2018_63
Hayer-Zillgen M, Brüss M, Bönisch H (2002) Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol 136:829–836. https://doi.org/10.1038/sj.bjp.0704785
He Q, Wang Q, Yuan C, Wang Y (2017) Downregulation of miR-7116-5p in microglia by MPP+ sensitizes TNF-α production to induce dopaminergic neuron damage. Glia 65:1251–1263. https://doi.org/10.1002/glia.23153
Hendrickx R, Johansson JG, Lohmann C, Jenvert RM, Blomgren A, Borjesson L, Gustavsson L (2013) Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem 56:7232–7242. https://doi.org/10.1021/jm400966v
Hengen N, Lizer MH, Kidd RS (2011) Evaluation of genetic variations in organic cation transporter 3 in depressed and nondepressed subjects. ISRN Pharmacol 2011:161740. https://doi.org/10.5402/2011/161740
Hill JE, Gasser PJ (2013) Organic cation transporter 3 is densely expressed in the intercalated cell groups of the amygdala: anatomical evidence for a stress hormone-sensitive dopamine clearance system. J Chem Neuroanat 52:36–43. https://doi.org/10.1016/j.jchemneu.2013.04.007
Horton RE, Apple DA, Owens WA, Baganz NL, Cano S, Mitchell NC, Vitela M, Gould GG, Koek W, Daws LC (2013) Decynium-22 enhances SSRI-induced antidepressant-like effects in mice: uncovering novel targets to treat depression. J Neurosci 33(25):10534–10543. https://doi.org/10.1523/JNEUROSCI.5687-11.2013
Hu T, Wang L, Pan X, Qi H (2016) Novel compound, organic cation transporter 3 detection agent and organic cation transporter 3 activity inhibitor, WO2015002150: a patent evaluation. Expert Opin Ther Pat 26(8):857–860. https://doi.org/10.1080/13543776.2016.1180364
Inazu M, Takeda H, Matsumiya T (2003) Expression and functional characterization of the extraneuronal monoamine transporter in normal human astrocytes. J Neurochem 84:43–52. https://doi.org/10.1046/j.1471-4159.2003.01566.x
Inazu M, Takeda H, Matsumiya T (2005) Molecular and functional characterization of an Na+-independent choline transporter in rat astrocytes. J Neurochem 94:1427–1437. https://doi.org/10.1111/j.1471-4159.2005.03299.x
Jonker JW, Wagenaar E, Mol CAAM, Buitelaar M, Koepsell H, Smit JW, Schinkel AH (2001) Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol Cell Biol 21(16):5471–5477. https://doi.org/10.1128/MCB.21.16.5471-5477.2001
Jonker JW, Wagenaar W, Van Eijl S, Schinkel AH (2003) Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol 23(21):7902–7908. https://doi.org/10.1128/mcb.23.21.7902-7908.2003
Kaidanovich-Beilin O, Milman A, Weizman A, Pick CG, Eldar-Finkelman H (2004) Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol Psychiatry 55(8):781–784. https://doi.org/10.1016/j.biopsych.2004.01.008
Kido Y, Matsson P, Giacomini KM (2011) Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. J Med Chem 54:4548–4558. https://doi.org/10.1021/jm2001629
Kitaichi K, Fukuda M, Nakayama H, Aoyama N, Ito Y, Fujimoto Y, Takagi K, Takagi K, Hasegawa T (2005) Behavioral changes following antisense oligonucleotide-induced reduction of organic cation transporter-3 in mice. Neurosci Lett 382:195–200. https://doi.org/10.1016/j.neulet.2005.03.014
Koepsell H (2020) Organic cation transporters in health and disease. Pharmacol Rev 72:253–319. https://doi.org/10.1124/pr.118.015578
Koepsell H (2021) General overview of organic cation transporters in the brain. Handb Exp Pharmacol. https://doi.org/10.1007/164_2021_449
Kölz C, Schaeffeler E, Schwab M, Nies AT (2021) Genetic and epigenetic regulation of organic cation transporters. Handb Exp Pharmacol. https://doi.org/10.1007/164_2021_450
Krause-Heuer AM, Fraser-Spears R, Dobrowolski JC, Ashford ME, Wyatt NA, Roberts MP, Gould GG, Cheah W-C, Ng CKL, Bhadbhade M, Zhang B, Greguric I, Wheate NJ, Kumar N, Koek W, Callaghan PD, Daws LC, Fraser BH (2017) Evaluation of the antidepressant therapeutic potential of isocyanine and pseudoisocyanine analogues of the organic cation decynium-22. Eur J Med Chem 137:476–487. https://doi.org/10.1016/j.ejmech.2017.06.011
Lazar A, Walitza S, Jetter A, Gerlach M, Warnke A, Herpertz-Dahlmann B, Gründemann D, Grimberg G, Schulz E, Remschmidt H, Wewetzer C, Schömig E (2008) Novel mutations of the extraneuronal monoamine transporter gene in children and adolescents with obsessive-compulsive disorder. Int J Neuropsychopharmacol 11(1):35–48. https://doi.org/10.1017/S1461145707007742
Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274:1527–1531. https://doi.org/10.1126/science.274.5292.1527
Lichtensteiger W, Mutzner U, Langemann H (1967) Uptake of 5-hydroxytryptamine and 5-hydroxytryptophan by neurons of the central nervous system normally containing catecholamines. J Neurochem 14:489–497. https://doi.org/10.1111/j.1471-4159.1967.tb09548.x
Lyer KA, Alix K, Eltit J, Solis E, Pan X, Argade MD, Khatri S, De Felice LJ, Sweet DH, Schulte MK, Dukat M (2019) Multi-modal antidepressant-like action of 6- and 7-chloro-2-aminodihydroquinazolines in the mouse tail suspension test. Psychopharmacology (Berl) 236(7):2093–2104. https://doi.org/10.1007/s00213-019-05203-5
Maier J, Niello M, Rudin D, Daws LC, Sitte HH (2021) The interaction of organic cation transporters 1-3 and PMAT with psychoactive substances. Handb Exp Pharmacol. https://doi.org/10.1007/164_2021_469
Männistö PT, Kaakkola S (1999) Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51:593–628. https://doi.org/10.1016/B978-0-12-381326-8.00005-3
Marcinkiewcz CA, Devine DP (2015) Modulation of OCT3 expression by stress, and antidepressant-like activity of decynium-22 in an animal model of depression. Pharmacol Biochem Behav 131:33–41. https://doi.org/10.1016/j.pbb.2015.01.004
Massmann V, Edemir B, Schlatter E, Al-Monajjed R, Harrach S, Klassen P, Holle SK, Sindic A, Dobrivojevic M, Pavenstädt H, Ciarimboli G (2014) The organic cation transporter 3 (OCT3) as molecular target of psychotropic drugs: transport characteristics and acute regulation of cloned murine OCT3. Pflugers Arch Eur J Physiol 466:517–527. https://doi.org/10.1007/s00424-013-1335-8
Maswood S, Truitt W, Hotema M, Caldarola-Pastuszka M, Uphouse L (1999) Estrous cycle modulation of extracellular serotonin in mediobasal hypothalamus: role of the serotonin transporter and terminal autoreceptors. Brain Res 831:146–154. https://doi.org/10.1016/s0006-8993(99)01439-0
Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, Murrough JW (2012) Ketamine for treatment-resistant unipolar depression. CNS Drugs 26(3):189–204. https://doi.org/10.2165/11599770-000000000-00000
Mathews TA, Fedele DE, Coppelli FM, Avila AM, Murphy DL, Andrews AM (2004) Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression. J Neurosci Methods 140:169–181. https://doi.org/10.1016/j.jneumeth.2004.05.017
Mathews DC, Henter ID, Zarate CA Jr (2012) Targeting the glutamatergic system to treat major depressive disorder. Drugs 72(10):1313–1333. https://doi.org/10.2165/11633130-000000000-00000
Mayer FP, Schmid D, Owens WA, Gould GG, Apuschkin M, Kudlacek O, Salzer I, Boehm S, Chiba P, Williams PH, Wu HH, Gether U, Koek W, Daws LC, Sitte HH (2018) An unsuspected role for organic cation transporter 3 in the actions of amphetamine. Neuropsychopharmacology 43:2408–2417. https://doi.org/10.1038/s41386-018-0053-5
McEwen BS (2008) Central effects of stress hormones in health and disease: understanding the protective and damaging effects of stress and stress mediators. Eur J Pharmacol 583:174–185. https://doi.org/10.1016/j.ejphar.2007.11.071
Miura Y, Yoshikawa T, Naganuma F, Nakamura T, Iida T, Kárpáti A, Matsuzawa T, Mogi A, Harada A, Yanai K (2017) Characterization of murine polyspecific monoamine transporters. FEBS Open Bio 7:237–248. https://doi.org/10.1002/2211-5463.12183
Monteggia LM, Zarate C Jr (2015) Antidepressant actions of ketamine: from molecular mechanisms to clinical practice. Curr Opin Neurobiol 30:139–143. https://doi.org/10.1016/j.conb.2014.12.004
Mooney JJ, Samson JA, Hennen J, Pappalardo K, McHale N, Alpert J, Koutsos M, Schildkraut JJ (2008) Enhanced norepinephrine output during long-term desipramine treatment: a possible role for the extraneuronal monoamine transporter (SLC22A3). J Psychiatr Res 42:605–611. https://doi.org/10.1016/j.jpsychires.2007.07.009
Mozhui K, Karlsson RM, Kash TL, Ihne J, Norcross M, Patel S, Farrell MR, Hill EE, Graybeal C, Martin KP, Camp M, Fitzgerald PJ, Ciobanu DC, Sprengel R, Mishina M, Wellman CL, Winder DG, Williams RW, Holmes A (2010) Strain differences in stress responsivity are associated with divergent amygdala gene expression and glutamate-mediated neuronal excitability. J Neurosci 30:5357–5367. https://doi.org/10.1523/JNEUROSCI.5017-09.2010
O’Brien WT, Harper AD, Jové F, Woodgett JR, Maretto S, Piccolo S, Klein PS (2004) Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 24(30):6791–6798. https://doi.org/10.1523/JNEUROSCI.4753-03.2004
Orrico-Sanchez A, Chausset-Boissarie L, Alves de Sousa R, Coutens B, Amin SR, Vialou V, Louis F, Hessani A, Dansette PM, Zornoza T, Gruszczynski C, Giros B, Guiard BP, Acher F, Pietrancosta N, Gautron S (2020) Antidepressant efficacy of a selective organic cation transporter blocker in a mouse model of depression. Mol Psychiatry 25:1245–1259. https://doi.org/10.1038/s41380-019-0548-4
Polter A, Beurel E, Yang S, Garner R, Song L, Miller CA, Sweatt JD, McMahon L, Bartolucci AA, Li X, Jope RS (2010) Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology 35(8):1761–1774. https://doi.org/10.1038/npp.2010.43
Rahman Z, Ring RH, Young K, Platt B, Lin Q, Schechter LE, Rosenzweig-Lipson S, Beyer CE (2008) Inhibition of uptake 2 (or extraneuronal monoamine transporter) by normetanephrine potentiates the neurochemical effects of venlafaxine. Brain Res 1203:68–78. https://doi.org/10.1016/j.brainres.2008.01.062
Ruhé HG, Huyser J, Swinkels JA, Schene AH (2006) Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: systematic review. Br J Psychiatry 189:309–316. https://doi.org/10.1192/bjp.bp.105.018325
Sakata T, Anzai N, Kimura T, Miura D, Fukutomi T, Takeda M, Sakurai H, Endou HJ (2010) Functional analysis of human organic cation transporter OCT3 (SLC22A3) polymorphisms. Pharmacol Sci 113(3):263–266. https://doi.org/10.1254/jphs.09331sc
Schildkraut JJ, Mooney JJ (2004) Toward a rapidly acting antidepressant: the normetanephrine and extraneuronal monoamine transporter (uptake 2) hypothesis. Am J Psychiatry 161:909–911. https://doi.org/10.1176/appi.ajp.161.5.909
Schmitt A, Mössner R, Gossmann A, Fishcer IG, Gorboulev V, Murphy DL, Koepsell H, Lesch KP (2003) Organic cation transporter capable of transporting serotonin is up-regulated in serotonin transporter-deficient mice. J Neurosci Res 71:701–709. https://doi.org/10.1002/jnr.10521
Shaskan EG, Snyder SH (1970) Kinetics of serotonin accumulation into slices from rat brain: relationship to catecholamine uptake. J Pharmacol Exp Ther 175:404–418
Shen H-W, Hagino Y, Kobayashi H, Shinohara-Tanaka K, Ikeda K, Yamamoto H, Yamamoto T, Lesch K-P, Murphy DL, Hall FS, Uhl GR, Sora I (2004) Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Neuropsychopharmacology 29:1790–1799. https://doi.org/10.1038/sj.npp.1300476
Sorge RE, Martin LJ, Isbester KA, Sotocinal SG, Rosen S, Tuttle AH, Wieskopf JS, Acland EL, Dokova A, Kadoura B, Leger P, Mapplebeck JCS, McPhail M, Delaney A, Wigerblad G, Schumann AP, Quinn T, Frasnelli J, Svensson CI, Sternberg WF, Mogil JS (2014) Olfactory exposure to males, including men, causes stress and related analgesia in rodents. Nature Meth 11(6):629–634. https://doi.org/10.1038/NMETH.2935
Stone EA, Lin Y (2008) An anti-immobility effect of exogenous corticosterone in mice. Eur J Pharmacol 580:135–142. https://doi.org/10.1016/j.ejphar.2007.10.045
Sweet DH (2021) Organic cation transporter expression and function in the CNS. Handb Exp Pharmacol. https://doi.org/10.1007/164_2021_463
Swiergiel AH, Leskov IL, Dunn AJ (2008) Effects of chronic and acute stressors and CRF on depression-like behavior in mice. Behav Brain Res 186:32–40. https://doi.org/10.1016/j.bbr.2007.07.018
Tranter R, O’Donovan C, Chandarana P, Kennedy S (2002) Prevalence and outcome of partial remission in depression. J Psychiatry Neurosci 27(4):241–247
Vialou V, Amphoux A, Zwart R, Giros B, Gautron S (2004) Organic cation transporter 3 (Slc22a3) is implicated in salt-intake regulation. J Neurosci 24:2846–2851. https://doi.org/10.1523/JNEUROSCI.5147-03.2004
Vialou V, Balasse L, Dumas S, Giros B, Gautron S (2007) Neurochemical characterization of pathways expressing plasma membrane monoamine transporter in the rat brain. Neuroscience 144:616–622. https://doi.org/10.1016/j.neuroscience.2006.09.058
Vialou V, Balasse L, Callebert J, Launay J-M, Giros B, Gautron S (2008) Altered aminergic neurotransmission in the brain of organic cation transporter 3-deficient mice. J Neurochem 106:1471–1482. https://doi.org/10.1111/j.1471-4159.2008.05506.x
Vieira LS, Wang J (2021) Brain plasma membrane monoamine transporter in health and disease. Handb Exp Pharmacol. https://doi.org/10.1007/164_2021_446
Wang J (2016) The plasma membrane monoamine transporter (PMAT): structure, function, and role in organic cation disposition. Clin Pharmacol Ther 100:489–499. https://doi.org/10.1002/cpt.442
Wilhelm K, Mitchell PB, Niven H, Finch A, Wedgwood L, Scimone A, Blair IP, Parker G, Schofield PR (2006) Life events, first depression onset and the serotonin transporter gene. Br J Psychiatry 188:210–215. https://doi.org/10.1192/bjp.bp.105.009522
World Health Organization (2017) Depression and other common mental disorders: global health estimates. World Health Organization. License: CC BY-NC-SA 3.0 IGO. https://apps.who.int/iris/handle/10665/254610
Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V (1998) Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem 273:32776–32786. https://doi.org/10.1074/jbc.273.49.32776
Wu K-C, Lu Y-H, Peng Y-H, Hsu L-C, Lin C-J (2015) Effects of lipopolysaccharide on the expression of plasma membrane monoamine transporter (PMAT) at the blood-brain barrier and its implications to the transport of neurotoxins. J Neurochem 135:1178–1188. https://doi.org/10.1111/jnc.13363
Wultsch T, Grimberg G, Schmitt A, Painsipp E, Wetzstein H, Frauke A, Breitenkamp S, Gründemann D, Schömig E, Lesch K-P, Gerlach M, Reif A (2009) Decreased anxiety in mice lacking organic cation transporter 3. J Neural Transm 116:89–697. https://doi.org/10.1007/s00702-009-0205-1
Xu Z, Hou B, Zhang Y, Gao Y, Wu Y, Zhao S, Zhang C (2009) Antidepressive behaviors induced by enriched environment might be modulated by glucocorticoid levels. Eur Neuropsychopharmacol 19:868–875. https://doi.org/10.1016/j.euroneuro.2009.07.004
Yoshikawa T, Naganuma F, Iida T, Nakamura T, Harada R, Mohsen AS, Kasajima A, Sasano H, Yanai K (2013) Molecular mechanism of histamine clearance by primary human astrocytes. Glia 61:905–916. https://doi.org/10.1002/glia.22484
Zhao Y, Xie W, Dai J, Wang Z, Huang Y (2009) The varying effects of short-term and long-term corticosterone injections on depression-like behavior in mice. Brain Res 1261:82–90. https://doi.org/10.1016/j.brainres.2008.12.083
Zhu H-J, Appel DI, Gründemann D, Richelson E, Markowitz JS (2012) Evaluation of organic cation transporter 3 (SLC22A3) inhibition as a potential mechanism of antidepressant action. Pharmacol Res 65:491–496. https://doi.org/10.1016/j.phrs.2012.01.008
Zwart R, Verhaagh S, Buitelaar M, Popp-Snijders C, Barlow DP (2001) Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice. Mol Cell Biol 21:4188–4196. https://doi.org/10.1128/MCB.21.13.4188-4196.2001
Acknowledgements
The author would like to thank Dr. Glenn Toney for his critical reading of this manuscript, as well as support from R01 MH093320.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Daws, L.C. (2021). Organic Cation Transporters in Psychiatric Disorders. In: Daws, L.C. (eds) Organic Cation Transporters in the Central Nervous System. Handbook of Experimental Pharmacology, vol 266. Springer, Cham. https://doi.org/10.1007/164_2021_473
Download citation
DOI: https://doi.org/10.1007/164_2021_473
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-82983-4
Online ISBN: 978-3-030-82984-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)